Does the media favor ACRV or KYNB?

In the previous week, Acrivon Therapeutics had 7 more articles in the media than Kyntra Bio. MarketBeat recorded 9 mentions for Acrivon Therapeutics and 2 mentions for Kyntra Bio. Kyntra Bio's average media sentiment score of 0.89 beat Acrivon Therapeutics' score of 0.26 indicating that Kyntra Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acrivon Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TELO or KYNB?

In the previous week, Telomir Pharmaceuticals had 1 more articles in the media than Kyntra Bio. MarketBeat recorded 3 mentions for Telomir Pharmaceuticals and 2 mentions for Kyntra Bio. Telomir Pharmaceuticals' average media sentiment score of 1.61 beat Kyntra Bio's score of 0.89 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telomir Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, KYNB or CRDF?

Kyntra Bio has higher revenue and earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kyntra Bio $6.44M 2.33 $183.45M $45.30 0.08 Cardiff Oncology $590K 102.05 -$45.85M -$0.60 N/A

Does the media refer more to KYNB or CRDF?

In the previous week, Kyntra Bio and Kyntra Bio both had 2 articles in the media. Kyntra Bio's average media sentiment score of 0.89 beat Cardiff Oncology's score of 0.78 indicating that Kyntra Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardiff Oncology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate KYNB or KVAC?

Kyntra Bio presently has a consensus price target of $36.80, indicating a potential upside of 894.33%. Given Kyntra Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Kyntra Bio is more favorable than Keen Vision Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kyntra Bio 2 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.43 Keen Vision Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation and earnings, KYNB or KVAC?

Kyntra Bio has higher revenue and earnings than Keen Vision Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kyntra Bio $6.44M 2.33 $183.45M $45.30 0.08 Keen Vision Acquisition N/A N/A N/A N/A N/A

Is KYNB or KVAC more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to Keen Vision Acquisition's net margin of 0.00%. Company Net Margins Return on Equity Return on Assets Kyntra Bio 2,199.13% N/A -47.27% Keen Vision Acquisition N/A N/A N/A

Do analysts prefer APLM or KYNB?

Kyntra Bio has a consensus price target of $36.80, indicating a potential upside of 894.33%. Given Kyntra Bio's stronger consensus rating and higher possible upside, analysts plainly believe Kyntra Bio is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kyntra Bio 2 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.43

Which has higher earnings & valuation, APLM or KYNB?

Kyntra Bio has lower revenue, but higher earnings than Apollomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 6.49 -$10.94M N/A N/A Kyntra Bio $6.44M 2.33 $183.45M $45.30 0.08

Is APLM or KYNB more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to Apollomics' net margin of 0.00%. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Kyntra Bio 2,199.13% N/A -47.27%

Does the media refer more to APLM or KYNB?

In the previous week, Apollomics and Apollomics both had 2 articles in the media. Apollomics' average media sentiment score of 0.91 beat Kyntra Bio's score of 0.89 indicating that Apollomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apollomics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Kyntra Bio (KYNB) Competitors

$3.68 +0.11 (+3.08%)

Closing price 04:00 PM Eastern

Extended Trading

$3.68 -0.01 (-0.14%)

As of 07:56 PM Eastern

Compare

KYNB vs. ACRV, TELO, CRDF, KVAC, and APLM

Should you buy Kyntra Bio stock or one of its competitors? Kyntra Bio's main competitors and comparable companies include Acrivon Therapeutics (ACRV), Telomir Pharmaceuticals (TELO), Cardiff Oncology (CRDF), Keen Vision Acquisition (KVAC), and Apollomics (APLM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kyntra Bio compare to Acrivon Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and Kyntra Bio (NASDAQ:KYNB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Kyntra Bio has higher revenue and earnings than Acrivon Therapeutics. Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$1.88	N/A
Kyntra Bio	$6.44M	2.33	$183.45M	$45.30	0.08

Acrivon Therapeutics has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

Kyntra Bio has a net margin of 2,199.13% compared to Acrivon Therapeutics' net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-70.14%	-61.60%
Kyntra Bio	2,199.13%	N/A	-47.27%

In the previous week, Acrivon Therapeutics had 7 more articles in the media than Kyntra Bio. MarketBeat recorded 9 mentions for Acrivon Therapeutics and 2 mentions for Kyntra Bio. Kyntra Bio's average media sentiment score of 0.89 beat Acrivon Therapeutics' score of 0.26 indicating that Kyntra Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acrivon Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Acrivon Therapeutics currently has a consensus target price of $13.50, indicating a potential upside of 746.39%. Kyntra Bio has a consensus target price of $36.80, indicating a potential upside of 894.33%. Given Kyntra Bio's higher probable upside, analysts plainly believe Kyntra Bio is more favorable than Acrivon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Kyntra Bio	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are owned by institutional investors. 10.5% of Acrivon Therapeutics shares are owned by company insiders. Comparatively, 4.2% of Kyntra Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Kyntra Bio beats Acrivon Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Kyntra Bio compare to Telomir Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and Kyntra Bio (NASDAQ:KYNB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

Kyntra Bio has higher revenue and earnings than Telomir Pharmaceuticals. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.89	N/A
Kyntra Bio	$6.44M	2.33	$183.45M	$45.30	0.08

Telomir Pharmaceuticals currently has a consensus price target of $4.00, suggesting a potential upside of 497.91%. Kyntra Bio has a consensus price target of $36.80, suggesting a potential upside of 894.33%. Given Kyntra Bio's stronger consensus rating and higher possible upside, analysts clearly believe Kyntra Bio is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Kyntra Bio	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Telomir Pharmaceuticals has a beta of -0.19, meaning that its stock price is 119% less volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market.

72.7% of Kyntra Bio shares are held by institutional investors. 16.4% of Telomir Pharmaceuticals shares are held by insiders. Comparatively, 4.2% of Kyntra Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Kyntra Bio has a net margin of 2,199.13% compared to Telomir Pharmaceuticals' net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-107.89%	-94.72%
Kyntra Bio	2,199.13%	N/A	-47.27%

In the previous week, Telomir Pharmaceuticals had 1 more articles in the media than Kyntra Bio. MarketBeat recorded 3 mentions for Telomir Pharmaceuticals and 2 mentions for Kyntra Bio. Telomir Pharmaceuticals' average media sentiment score of 1.61 beat Kyntra Bio's score of 0.89 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telomir Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kyntra Bio beats Telomir Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

How does Kyntra Bio compare to Cardiff Oncology?

Kyntra Bio (NASDAQ:KYNB) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

In the previous week, Kyntra Bio and Kyntra Bio both had 2 articles in the media. Kyntra Bio's average media sentiment score of 0.89 beat Cardiff Oncology's score of 0.78 indicating that Kyntra Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardiff Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kyntra Bio has a net margin of 2,199.13% compared to Cardiff Oncology's net margin of -7,885.43%. Kyntra Bio's return on equity of 0.00% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-47.27%
Cardiff Oncology	-7,885.43%	-103.10%	-75.52%

Kyntra Bio has higher revenue and earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	2.33	$183.45M	$45.30	0.08
Cardiff Oncology	$590K	102.05	-$45.85M	-$0.60	N/A

72.7% of Kyntra Bio shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 4.2% of Kyntra Bio shares are owned by insiders. Comparatively, 8.8% of Cardiff Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Kyntra Bio currently has a consensus target price of $36.80, indicating a potential upside of 894.33%. Cardiff Oncology has a consensus target price of $7.50, indicating a potential upside of 868.99%. Given Kyntra Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Kyntra Bio is more favorable than Cardiff Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Kyntra Bio has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market.

Summary

Kyntra Bio beats Cardiff Oncology on 12 of the 15 factors compared between the two stocks.

How does Kyntra Bio compare to Keen Vision Acquisition?

Kyntra Bio (NASDAQ:KYNB) and Keen Vision Acquisition (NASDAQ:KVAC) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Kyntra Bio has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Keen Vision Acquisition has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market.

In the previous week, Kyntra Bio had 2 more articles in the media than Keen Vision Acquisition. MarketBeat recorded 2 mentions for Kyntra Bio and 0 mentions for Keen Vision Acquisition. Kyntra Bio's average media sentiment score of 0.89 beat Keen Vision Acquisition's score of 0.00 indicating that Kyntra Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Kyntra Bio	Positive
Keen Vision Acquisition	Neutral

Kyntra Bio has a net margin of 2,199.13% compared to Keen Vision Acquisition's net margin of 0.00%.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-47.27%
Keen Vision Acquisition	N/A	N/A	N/A

72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 51.7% of Keen Vision Acquisition shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by insiders. Comparatively, 80.2% of Keen Vision Acquisition shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Kyntra Bio has higher revenue and earnings than Keen Vision Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	2.33	$183.45M	$45.30	0.08
Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A

Kyntra Bio presently has a consensus price target of $36.80, indicating a potential upside of 894.33%. Given Kyntra Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Kyntra Bio is more favorable than Keen Vision Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Keen Vision Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Kyntra Bio beats Keen Vision Acquisition on 9 of the 11 factors compared between the two stocks.

How does Kyntra Bio compare to Apollomics?

Apollomics (NASDAQ:APLM) and Kyntra Bio (NASDAQ:KYNB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

19.1% of Apollomics shares are held by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Apollomics and Apollomics both had 2 articles in the media. Apollomics' average media sentiment score of 0.91 beat Kyntra Bio's score of 0.89 indicating that Apollomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apollomics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kyntra Bio has a consensus price target of $36.80, indicating a potential upside of 894.33%. Given Kyntra Bio's stronger consensus rating and higher possible upside, analysts plainly believe Kyntra Bio is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kyntra Bio	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Kyntra Bio has lower revenue, but higher earnings than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	6.49	-$10.94M	N/A	N/A
Kyntra Bio	$6.44M	2.33	$183.45M	$45.30	0.08

Kyntra Bio has a net margin of 2,199.13% compared to Apollomics' net margin of 0.00%.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Kyntra Bio	2,199.13%	N/A	-47.27%

Apollomics has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market.

Summary

Kyntra Bio beats Apollomics on 7 of the 12 factors compared between the two stocks.

Get Kyntra Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KYNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KYNB vs. The Competition

Export

Metric	Kyntra Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$14.90M	$4.17B	$7.89B	$12.22B
Dividend Yield	N/A	3.64%	2.47%	4.44%
P/E Ratio	0.08	25.46	35.35	30.86
Price / Sales	2.31	16.28	8.40	5.81
Price / Cash	N/A	26.87	22.22	22.66
Price / Book	-0.88	4.21	4.43	3.79
Net Income	$183.45M	-$22.76M	$3.50B	$390.16M
7 Day Performance	-7.07%	-1.08%	-0.97%	-1.10%
1 Month Performance	-39.77%	-6.80%	-4.07%	-6.19%
1 Year Performance	N/A	1.72%	2.04%	-5.75%

Kyntra Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KYNB Kyntra Bio	3.8255 of 5 stars	$3.68 +3.1%	$36.80 +900.0%	N/A	$14.90M	$6.44M	0.08	34	Analyst Downgrade
ACRV Acrivon Therapeutics	3.0585 of 5 stars	$1.61 +2.5%	$13.50 +738.5%	-22.7%	$68.99M	N/A	N/A	76	Upcoming Earnings Analyst Forecast
TELO Telomir Pharmaceuticals	2.1933 of 5 stars	$0.71 -9.0%	$4.00 +463.3%	-58.2%	$67.42M	N/A	N/A	5	Positive News Earnings Report Gap Up
CRDF Cardiff Oncology	1.8661 of 5 stars	$0.80 +5.3%	$7.50 +843.0%	-64.4%	$65.68M	$590K	N/A	31	Upcoming Earnings Analyst Upgrade
KVAC Keen Vision Acquisition	N/A	$11.51 flat	N/A	N/A	$63.37M	N/A	N/A	N/A	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KYNB) was last updated on 11/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kyntra Bio (KYNB) Competitors

KYNB vs. ACRV, TELO, CRDF, KVAC, and APLM

How does Kyntra Bio compare to Acrivon Therapeutics?

Summary

How does Kyntra Bio compare to Telomir Pharmaceuticals?

Summary

How does Kyntra Bio compare to Cardiff Oncology?

Summary

How does Kyntra Bio compare to Keen Vision Acquisition?

Summary

How does Kyntra Bio compare to Apollomics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYNB vs. The Competition

Kyntra Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kyntra Bio (KYNB) Competitors

KYNB vs. ACRV, TELO, CRDF, KVAC, and APLM

How does Kyntra Bio compare to Acrivon Therapeutics?

Which has preferable earnings & valuation, ACRV or KYNB?

Which has more volatility & risk, ACRV or KYNB?

Is ACRV or KYNB more profitable?

Does the media favor ACRV or KYNB?

Do analysts recommend ACRV or KYNB?

Do insiders and institutionals believe in ACRV or KYNB?

Summary

How does Kyntra Bio compare to Telomir Pharmaceuticals?

Which has better valuation and earnings, TELO or KYNB?

Do analysts prefer TELO or KYNB?

Which has more risk and volatility, TELO or KYNB?

Do institutionals & insiders hold more shares of TELO or KYNB?

Is TELO or KYNB more profitable?

Does the media prefer TELO or KYNB?

Summary

How does Kyntra Bio compare to Cardiff Oncology?

Does the media refer more to KYNB or CRDF?

Is KYNB or CRDF more profitable?

Which has stronger valuation & earnings, KYNB or CRDF?

Do insiders & institutionals believe in KYNB or CRDF?

Do analysts prefer KYNB or CRDF?

Which has more volatility and risk, KYNB or CRDF?

Summary

How does Kyntra Bio compare to Keen Vision Acquisition?

Which has more risk & volatility, KYNB or KVAC?

Does the media favor KYNB or KVAC?

Is KYNB or KVAC more profitable?

Do insiders and institutionals believe in KYNB or KVAC?

Which has preferable valuation and earnings, KYNB or KVAC?

Do analysts rate KYNB or KVAC?

Summary

How does Kyntra Bio compare to Apollomics?

Do institutionals and insiders believe in APLM or KYNB?

Does the media refer more to APLM or KYNB?

Do analysts prefer APLM or KYNB?

Which has higher earnings & valuation, APLM or KYNB?

Is APLM or KYNB more profitable?

Which has more risk & volatility, APLM or KYNB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYNB vs. The Competition

Kyntra Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools